AST-301 not checked

Aston Sci. Inc. · pNGVL3-hICD

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Gastric Cancer
Main trialPhase 2
“The purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have completed the standard adjuvant treatment (including those who discontinued the standard adjuvant treatment due to intolerance). Participants will be randomized 1:1 to either Arm 1 (Q3W, 3 cycles), or Arm 2 (Q3W, 6 cycles) of the study. Safety Monitoring Committee (SMC) will oversee safety of study at 25% (6 participants), 50% (12 participants), and 75% (18 participants) of…”In the company’s words, NCT05771584 on ClinicalTrials.gov
Other names
pNGVL3-hICD

Other drugs for Gastric Cancer

All 208 drugs for Gastric Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 9 Feb 2027 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
Phase 2Terminated 31 May 2024 Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AST-301

Following is part of Solo: you see every change to AST-301 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in